Answers are grounded in this paper and cite their sources.
Background: Relapses are the defining clinical feature of relapsing-remitting multiple sclerosis, but it remains uncertain whether disease-modifying treatments influence relapse severity or recovery once a relapse occurs. We investigated whether disease-modifying treatment exposure affects the severity of and recovery from clinical relapses across four pivotal phase 3 relapsing-remitting multiple sclerosis trials. Methods: We used logistic regression models to assess predictors of severe first relapse (Expanded Disability Status Scale worsening > 1.0 point), and Cox proportional hazards models to evaluate factors associated with time to recovery. Predictors included age, sex, disease duration, baseline Expanded Disability Status Scale, T2 lesion volume, contrast-enhancing lesions, relapse severity, corticosteroid treatment and treatment arm. Results: Across all trials, disease-modifying treatments significantly reduced the annualized relapse rate (p < 0.0001) compared to placebo or interferon as an active comparator, but were not associated with relapse severity or recovery time. Relapse recovery followed a similar two-phase course in all trials, with most recovery occurring within 90–120 days. Treatment arm and corticosteroid use were not significantly associated with the time to recovery in any dataset. Conclusions: While disease-modifying treatments reduce relapse frequency, they did not modify relapse severity or recovery once a relapse occurred. These findings suggest that disease-modifying treatments primarily prevent inflammatory events rather than alter their clinical evolution.
No takes yet. Share an insight, caveat, or question.
Koch et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: